-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is only for medical professionals to read and reference BICENPRO tablets are currently the only single-tablet regimen recommended for PEP by the new Chinese guidelines
.
Post-exposure prophylaxis (PEP), also known as post-exposure prophylaxis, is a method for reducing the risk of HIV infection by taking specific antiviral drugs early (no more than 72 hours) after exposure to a high risk of infection in people who are not yet infected with HIV [1] ], is one of the important ways of clinical prevention of HIV virus
.
However, the completion rate of PEP users is low.
A meta-analysis of 97 studies from around the world showed that only 56.
6% of PEP users completed the 28-day program[2]
.
Of the studies included in this meta-analysis, 64% reported discontinuation of PEP due to adverse events [2]
.
How to better "break the situation", the 2021 new edition of "Chinese AIDS Diagnosis and Treatment Guidelines" provides "a new solution for single-chip blocking", let's take a look
.
1.
The new Chinese guidelines recommend for the first time that the single-chip blocking program PEP is divided into occupational exposure (oPEP) and non-occupational exposure (nPEP).
There is a risk of HIV infection due to contact with blood, tissue or other body fluids [1]
.
The latter refers to HIV exposure through personal behavior other than occupational exposure [1].
Commonly applicable groups include men who have sex with men and transgender women, negative sexual partners of HIV-infected persons, intravenous drug users, and victims of sexual assault.
etc.
[3]
.
Standardized use of the PEP regimen requires early initiation (within 72 hours), continuous medication (28 days), and a complete triple antiviral regimen [1]
.
BIC/FTC/TAF recommended by the new Chinese AIDS diagnosis and treatment guidelines is currently the only single-tablet regimen recommended for PEP [1].
(FTC), tenofovir alafenamide (TAF) and innovative integrase inhibitor bictegravir (BIC), it is a complete antiviral triple single-tablet preparation, one tablet a day, convenient to take [4]
.
2.
Monolithic blockade is easy to use, with high completion rate and high success rate[5] In January 2022, a single-center, investigator-initiated, open-label, prospective evaluation of PEP monolithic blockade regimen BIC/FTC/TAF Sexual, Phase IV study "Safety and Tolerability of Once Daily Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Post-Exposure Prophylaxis after Sexual Exposure" published in the journal J Acquir Immune Defic Syndr, mainly conducted at Boston Community Health Centers, The health center has been working to find new, effective, and better-tolerated PEP regimens
.
From August 2018 to March 2020, a total of 52 people using the single-chip blockade regimen BIC/FTC/TAF (28 days, 1 tablet per day) were included, with a median age of 37.
2 years.
The study used Pearson cards Square test and Fisher's exact test were used to evaluate the differences in side effects and protocol completion rates between BIC/FTC/TAF and previous PEP regimens
.
The results of this study showed that the completion rate of BIC/FTC/TAF was as high as 90.
4% for the single-chip blockade regimen, while the completion rate of other combination blocking regimens, such as AZT/3TC+PI or FTC/TDF+RAL regimens, were all lower than 60%.
, the difference is statistically significant
.
At the end of the study, there was no HIV positive case in the population using the single-chip blocking regimen, and the blocking success rate reached 100%
.
3.
Monolithic blockade is safe to use, with fewer adverse events [5] The above study also found that BIC/FTC/TAF as a monolithic blockade regimen is safe and well tolerated, and is better than the previous PEP regimen used by the Boston Community Health Center are better
.
When using the BIC/FTC/TAF monolithic blockade regimen, the most common side effects in PEP patients included nausea or vomiting (15.
4%), fatigue (9.
6%), and diarrhea (7.
7%)
.
Compared with historical blockade regimens containing zidovudine and protease inhibitors, the single-tablet blockade regimen had a reduced risk of any adverse reactions, including nausea/vomiting, fatigue, diarrhea/loose stools, headache, dizziness/dizziness, and Myalgia/joint pain
.
Compared with the emtricitabine/tenofovir + raltegravir potassium regimen, the incidences of diarrhea/loose stools, headache and dizziness/dizziness were lower in the monolithic blockade regimen, and the remaining adverse reactions were not statistically different, but Numerically decreased
.
Knock on the blackboard summary: Post-mortem blockade is the last line of defense against HIV infection.
The new guideline recommends BIC/FTC/TAF as the only single-chip blockade regimen.
Studies have shown that single-chip blockade has a better completion rate and fewer adverse events.
It is PEP New options are preferred
.
References: [1] Chinese Center for Disease Control and Prevention, AIDS and Hepatitis C Group, Infectious Diseases Branch of Chinese Medical Association.
Chinese AIDS diagnosis and treatment guidelines (2021 edition).
China AIDS and STD.
2021; 27(11): 1182-1201.
[ 2] AIDS.
2014 Nov 28; 28(18): 2721-7.
[3] Chinese Center for Disease Control and Prevention, STD and AIDS Prevention and Control Center.
Technical Guidelines for HIV Post-Exposure Prevention (Trial).
2020.
[4]https:/ / Acquir Immune Defic Syndr.
2022 Jan 4.
This information is for medical and scientific reference only and is not recommended in any way that is inconsistent with the prescribing information approved in your country Using this product,
.
Post-exposure prophylaxis (PEP), also known as post-exposure prophylaxis, is a method for reducing the risk of HIV infection by taking specific antiviral drugs early (no more than 72 hours) after exposure to a high risk of infection in people who are not yet infected with HIV [1] ], is one of the important ways of clinical prevention of HIV virus
.
However, the completion rate of PEP users is low.
A meta-analysis of 97 studies from around the world showed that only 56.
6% of PEP users completed the 28-day program[2]
.
Of the studies included in this meta-analysis, 64% reported discontinuation of PEP due to adverse events [2]
.
How to better "break the situation", the 2021 new edition of "Chinese AIDS Diagnosis and Treatment Guidelines" provides "a new solution for single-chip blocking", let's take a look
.
1.
The new Chinese guidelines recommend for the first time that the single-chip blocking program PEP is divided into occupational exposure (oPEP) and non-occupational exposure (nPEP).
There is a risk of HIV infection due to contact with blood, tissue or other body fluids [1]
.
The latter refers to HIV exposure through personal behavior other than occupational exposure [1].
Commonly applicable groups include men who have sex with men and transgender women, negative sexual partners of HIV-infected persons, intravenous drug users, and victims of sexual assault.
etc.
[3]
.
Standardized use of the PEP regimen requires early initiation (within 72 hours), continuous medication (28 days), and a complete triple antiviral regimen [1]
.
BIC/FTC/TAF recommended by the new Chinese AIDS diagnosis and treatment guidelines is currently the only single-tablet regimen recommended for PEP [1].
(FTC), tenofovir alafenamide (TAF) and innovative integrase inhibitor bictegravir (BIC), it is a complete antiviral triple single-tablet preparation, one tablet a day, convenient to take [4]
.
2.
Monolithic blockade is easy to use, with high completion rate and high success rate[5] In January 2022, a single-center, investigator-initiated, open-label, prospective evaluation of PEP monolithic blockade regimen BIC/FTC/TAF Sexual, Phase IV study "Safety and Tolerability of Once Daily Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Post-Exposure Prophylaxis after Sexual Exposure" published in the journal J Acquir Immune Defic Syndr, mainly conducted at Boston Community Health Centers, The health center has been working to find new, effective, and better-tolerated PEP regimens
.
From August 2018 to March 2020, a total of 52 people using the single-chip blockade regimen BIC/FTC/TAF (28 days, 1 tablet per day) were included, with a median age of 37.
2 years.
The study used Pearson cards Square test and Fisher's exact test were used to evaluate the differences in side effects and protocol completion rates between BIC/FTC/TAF and previous PEP regimens
.
The results of this study showed that the completion rate of BIC/FTC/TAF was as high as 90.
4% for the single-chip blockade regimen, while the completion rate of other combination blocking regimens, such as AZT/3TC+PI or FTC/TDF+RAL regimens, were all lower than 60%.
, the difference is statistically significant
.
At the end of the study, there was no HIV positive case in the population using the single-chip blocking regimen, and the blocking success rate reached 100%
.
3.
Monolithic blockade is safe to use, with fewer adverse events [5] The above study also found that BIC/FTC/TAF as a monolithic blockade regimen is safe and well tolerated, and is better than the previous PEP regimen used by the Boston Community Health Center are better
.
When using the BIC/FTC/TAF monolithic blockade regimen, the most common side effects in PEP patients included nausea or vomiting (15.
4%), fatigue (9.
6%), and diarrhea (7.
7%)
.
Compared with historical blockade regimens containing zidovudine and protease inhibitors, the single-tablet blockade regimen had a reduced risk of any adverse reactions, including nausea/vomiting, fatigue, diarrhea/loose stools, headache, dizziness/dizziness, and Myalgia/joint pain
.
Compared with the emtricitabine/tenofovir + raltegravir potassium regimen, the incidences of diarrhea/loose stools, headache and dizziness/dizziness were lower in the monolithic blockade regimen, and the remaining adverse reactions were not statistically different, but Numerically decreased
.
Knock on the blackboard summary: Post-mortem blockade is the last line of defense against HIV infection.
The new guideline recommends BIC/FTC/TAF as the only single-chip blockade regimen.
Studies have shown that single-chip blockade has a better completion rate and fewer adverse events.
It is PEP New options are preferred
.
References: [1] Chinese Center for Disease Control and Prevention, AIDS and Hepatitis C Group, Infectious Diseases Branch of Chinese Medical Association.
Chinese AIDS diagnosis and treatment guidelines (2021 edition).
China AIDS and STD.
2021; 27(11): 1182-1201.
[ 2] AIDS.
2014 Nov 28; 28(18): 2721-7.
[3] Chinese Center for Disease Control and Prevention, STD and AIDS Prevention and Control Center.
Technical Guidelines for HIV Post-Exposure Prevention (Trial).
2020.
[4]https:/ / Acquir Immune Defic Syndr.
2022 Jan 4.
This information is for medical and scientific reference only and is not recommended in any way that is inconsistent with the prescribing information approved in your country Using this product,
